Bristol-Myers Squibb Company (BMY)

56.22
0.33 0.58
NYSE : Health Care
Prev Close 56.55
Open 56.70
Day Low/High 56.05 / 56.73
52 Wk Low/High 49.03 / 77.12
Volume 7.66M
Avg Volume 10.16M
Exchange NYSE
Shares Outstanding 1.67B
Market Cap 94.51B
EPS 0.90
P/E Ratio 18.36
Div & Yield 1.56 (2.80%)

Latest News

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Bristol-Myers Squibb And GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

Bristol-Myers Squibb And GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc.

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio

Congressional Republicans who scrapped plans to overhaul the Office of Congressional Ethics might be regretting their decision. Senate Dems are asking for an investigation into HHS pick Tom Price.

Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration With Janssen To Evaluate Opdivo (nivolumab) In Combination With Darzalex (daratumumab)

Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration With Janssen To Evaluate Opdivo (nivolumab) In Combination With Darzalex (daratumumab)

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Bristol-Myers Squibb To Present At J.P. Morgan Healthcare Conference

Bristol-Myers Squibb To Present At J.P. Morgan Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will present at the J.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Bristol-Myers Squibb To Take Part At The Goldman Sachs Healthcare CEOs Unscripted: A View From The Top

Bristol-Myers Squibb To Take Part At The Goldman Sachs Healthcare CEOs Unscripted: A View From The Top

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 5, 2017, in Boston, Massachusetts.

Choppiness Usually Ends With Some Sort of Decline

Typically, the best way to get sentiment to turn is to take the indexes down.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Giovanni Caforio Named Chairman Of Bristol-Myers Squibb's Board Of Directors

Giovanni Caforio Named Chairman Of Bristol-Myers Squibb's Board Of Directors

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the company's Board of Directors has appointed Giovanni Caforio, M.

A Biotech Trio to Like Going Into 2017

A Biotech Trio to Like Going Into 2017

Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.

Bristol-Myers Commits Up to $1 Billion for Virus 'Armed' to Fight Tumors

Bristol-Myers Commits Up to $1 Billion for Virus 'Armed' to Fight Tumors

Terms of the deal include an upfront payment of $50 million plus up to $886 million in development, regulatory and sales-based milestones.

Analysts Mixed on Health Care Stocks in the New Year

Analysts Mixed on Health Care Stocks in the New Year

While there is deep uncertainty about how politics will affect the health care sector in the new year, analysts seem excited about some opportunities in pharmaceuticals.

'I Didn't Buy This Call,' Jim Cramer Says of Merck Downgrade

'I Didn't Buy This Call,' Jim Cramer Says of Merck Downgrade

TheStreet's Jim Cramer says he'd have gone the other way as Jefferies downgrades Merck stock.

The Best Biopharma CEOs of 2016 Are...

The Best Biopharma CEOs of 2016 Are...

The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.

Analysts' Actions -- Bristol-Myers, Merck, United Technologies and More

Analysts' Actions -- Bristol-Myers, Merck, United Technologies and More

Here are Monday's top research calls, including upgrades for Bristol-Myers Squibb and United Technologies, and a downgrade for Merck.

White House Kills Plan for Drug Price Cap

White House Kills Plan for Drug Price Cap

Pelosi, Schumer and nearly everyone else had asked Obama to deep-six the deal.

December Trades Bring Eggnog, Mistletoe -- and Some Coal

December Trades Bring Eggnog, Mistletoe -- and Some Coal

A couple of quick wins, a hedge/fade that didn't work, and 2 triggers not firing.

'Mad Money' Lightning Round: Hawaii Is Good but Alaska's Better

'Mad Money' Lightning Round: Hawaii Is Good but Alaska's Better

Jim Cramer says Hawaiian Holdings is 'pretty good,' but Alaska Air is even better.

Jim Cramer's 'Mad Money' Recap: How to Play Leapfrog in This Fast-Moving Market

Jim Cramer's 'Mad Money' Recap: How to Play Leapfrog in This Fast-Moving Market

Jim Cramer says stocks keep leapfrogging their peers in sectors like airlines and semiconductors.

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

Bristol-Myers Squibb Strengthens Capabilities With Evolution Of Its U.S. Geographic Footprint

Bristol-Myers Squibb Strengthens Capabilities With Evolution Of Its U.S. Geographic Footprint

Bristol-Myers Squibb Company (NYSE:BMY) today announced important changes to its U.

This Rally May Not Be Done, but It's Close

Friday’s action was enough for me to believe we’re near a real pullback.